{
  "docId": "019dd923-5ca1-7489-b638-e62bea0762fa",
  "docSlug": "78005f3a3554aa50",
  "documentTitle": "Refueling Innovation Engine Vaccines",
  "authorId": "McKinsey",
  "authorName": "McKinsey",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 26,
  "pageCount": 40,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "comparison_table",
  "function": "present_framework",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a side-by-side comparison structure to define evaluation criteria for vaccine development.",
  "elementsJson": [
    "comparison_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-e62bea0762fa/26",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "SOURCE: McKinsey",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfa39cfe-0588-4f74-987a-d40f8b64ce0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "table",
      "text": "Commercial attractiveness vs Technical Feasibility criteria",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95afe30a-be44-4198-b2ae-57303d9730d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Commercial attractiveness and technical feasibility vary by vaccine and vaccine archetype",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d83d66d-6e41-418d-8c43-4d1d3bcdb42c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "diagnostic-test",
      "slug": null,
      "matchId": "2de6f0c8-b622-43c0-b3f4-764df51854be",
      "evidence": "The slide provides a set of diagnostic questions to evaluate the viability of vaccine candidates.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "aed78475-3aec-4aeb-9912-10ba1bb79adb",
      "evidence": "The deck highlights the increasing costs and economic uncertainty of vaccine development.",
      "position": 0,
      "objective": "What are the costs of inaction in vaccine innovation?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}